Axsome Therapeutics, Inc.

NasdaqGM:AXSM 주식 보고서

시가총액: US$3.8b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Axsome Therapeutics 관리

관리 기준 확인 2/4

Axsome Therapeutics' CEO는 Herriot Tabuteau, Jan2012 에 임명되었습니다 의 임기는 12.42 년입니다. 총 연간 보상은 $ 9.90M, 7.6% 로 구성됩니다. 7.6% 급여 및 92.4% 보너스(회사 주식 및 옵션 포함). 는 $ 549.54K 가치에 해당하는 회사 주식의 0.015% 직접 소유합니다. 549.54K. 경영진과 이사회의 평균 재임 기간은 각각 5 년과 9.5 년입니다.

주요 정보

Herriot Tabuteau

최고 경영자

US$9.9m

총 보상

CEO 급여 비율7.6%
CEO 임기12.5yrs
CEO 소유권0.02%
경영진 평균 재임 기간5yrs
이사회 평균 재임 기간9.6yrs

최근 관리 업데이트

Recent updates

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 10

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13
Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03
Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14
Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Axsome And AXS-05: A Special Situation

May 02

Axsome: A Growth Transition

Apr 13

Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst

Apr 03

Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years

Mar 19

CEO 보상 분석

Herriot Tabuteau 의 보수는 Axsome Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$296m

Dec 31 2023US$10mUS$750k

-US$239m

Sep 30 2023n/an/a

-US$202m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$8mUS$685k

-US$187m

Sep 30 2022n/an/a

-US$160m

Jun 30 2022n/an/a

-US$150m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$8mUS$685k

-US$130m

Sep 30 2021n/an/a

-US$126m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$100m

Dec 31 2020US$7mUS$575k

-US$103m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$90m

Dec 31 2019US$5mUS$435k

-US$68m

Sep 30 2019n/an/a

-US$53m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$435k

-US$31m

Sep 30 2018n/an/a

-US$29m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$1mUS$435k

-US$29m

보상 대 시장: Herriot 의 총 보상 ($USD 9.90M )은 US 시장( $USD 6.80M ).

보상과 수익: 회사가 수익성이 없는 동안 Herriot 의 보상이 증가했습니다.

CEO

Herriot Tabuteau (56 yo)

12.5yrs

테뉴어

US$9,896,629

보상

Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...

리더십 팀

이름위치테뉴어보상소유권
Herriot Tabuteau
Founder12.5yrsUS$9.90m0.015%
$ 581.9k
Nick Pizzie
Chief Financial Officer6.2yrsUS$3.57m0.089%
$ 3.4m
Mark Jacobson
Chief Operating Officer8.8yrsUS$4.04m0.012%
$ 465.7k
Hunter Murdock
General Counsel & Secretary2.6yrsUS$3.06m0%
$ 0
Lori Englebert
Executive Vice President of Product Strategy3.9yrs데이터 없음데이터 없음
Ari Maizel
Executive VP & Head of Commercialless than a year데이터 없음데이터 없음

5.0yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: AXSM 의 관리팀은 노련하고 경험 (평균 재직 기간 5 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Herriot Tabuteau
Founder12.5yrsUS$9.90m0.015%
$ 581.9k
Roger Jeffs
Independent Lead Director9.6yrsUS$400.34k0.35%
$ 13.5m
Mark Saad
Independent Director9.6yrsUS$405.34k0.022%
$ 829.3k
Susan Mahony
Independent Directorless than a yearUS$417.48k0%
$ 0
Mark Coleman
Independent Director9.6yrsUS$427.84k0.031%
$ 1.2m

9.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: AXSM 의 이사회는 경험(평균 재직 기간 9.5 년)으로 간주됩니다.